https://investors.bms.com/iframes/press-releases/press-release-details/2024/FDA-Advisory-Committee-Votes-in-Favor-of-Bristol-Myers-Squibbs-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Multiple-Myeloma-in-Earlier-Lines-of-Therapy/default.aspx
https://myelomaresearchnews.com/news/car-t-cell-therapy-farvykti-favored-earlier-multiple-myeloma-treatment/
The ODAC advisory committee has voted in favour for 2 CAR-T therapies in earlier lines of treatment for multiple myeloma. Voting was convincing, bodes well for future CAR-T therapies in earlier lines of treatment.
https://investors.bms.com/iframes/press-releases/press-release-de...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.001(3.70%) |
Mkt cap ! $23.97M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.7¢ | $1.457K | 52.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1403547 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 140734 | 2 |
View Market Depth
| Last trade - 10.43am 07/05/2024 (20 minute delay) ? |
| CHM (ASX) Chart |